KLP Kapitalforvaltning AS Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

KLP Kapitalforvaltning AS purchased a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,200 shares of the company’s stock, valued at approximately $31,000.

A number of other large investors also recently modified their holdings of the business. US Bancorp DE bought a new position in shares of Tyra Biosciences in the fourth quarter valued at $50,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tyra Biosciences in the 4th quarter worth $149,000. Franklin Resources Inc. acquired a new stake in Tyra Biosciences during the 3rd quarter worth about $278,000. The Manufacturers Life Insurance Company purchased a new stake in Tyra Biosciences during the third quarter valued at about $333,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Tyra Biosciences in the third quarter worth about $593,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $7.96 on Friday. The business’s 50-day simple moving average is $10.73 and its 200-day simple moving average is $15.16. The firm has a market cap of $422.60 million, a price-to-earnings ratio of -4.94 and a beta of 1.19. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $30.83.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 21,998 shares of company stock worth $344,818. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.